A joint venture of Cipla, Cooper Pharma, and the Pharmaceutical Institute has constructed a new metered dose inhaler manufacturing plant in a suburb of Rabat, Morocco that opened officially as of October 14, 2018. The $6.4 million plant is situated on a 4,000 sq m site and has a capacity of 1.5 million MDIs per year.
Eleven of the 15 different SKUs of MDIs manufactured at the Ain El Aouda facility will be available in the Moroccan market for the first time, Cipla has confirmed. In addition to supplying inhalers for Morocco, the plant will make inhalers for export to other African countries.
Read an Ecofin report on the new facility.
